IRLAB Therapeutics AB (OSTO:IRLAB A) Quality Rank


OSTO:IRLAB A IRLAB Therapeutics AB OSTO:IRLAB A
36 GF Score
Price kr1.40
GF Value kr11.74
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is IRLAB Therapeutics AB Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

IRLAB Therapeutics AB Quality Rank Related Terms

OSTO:IRLAB A
36GF Score
IRLAB Therapeutics AB OSTO:IRLAB A
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is IRLAB Therapeutics AB (OSTO:IRLAB A) Overvalued in 2026?

Based on GuruFocus' analysis, IRLAB Therapeutics AB stock appears to be undervalued. The current stock price of kr1.40 is trading 88.1% below its estimated GF Value™ of kr11.74. GuruFocus considers IRLAB Therapeutics AB to be Possible Value Trap.

Key valuation signals for OSTO:IRLAB A:

  • Quality Rank:
  • GF Value™: kr11.74 vs. price of kr1.40 (88.1% below fair value)
  • GF Score™: 36/100 with 6 warning signs

No single metric tells the full story. See the OSTO:IRLAB A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IRLAB Therapeutics AB Business Description

Other Exchanges 6IRA:Germany
Address Arvid Wallgren Backe 20, Goteborg, SWE, 413 46
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds that aims to offer improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.
36GF Score

Get the complete analysis for OSTO:IRLAB A

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.40
Price
kr11.74
GF Value